Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility

Autor: Frank Z. Stancyzk, Lie H. Chen, Kerstin Hellwig, Annette Langer-Gould
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Physiology
lcsh:Medicine
Biochemistry
Body Mass Index
0302 clinical medicine
Medicine and Health Sciences
Young adult
lcsh:Science
education.field_of_study
030219 obstetrics & reproductive medicine
Multidisciplinary
Clinically isolated syndrome
Pharmaceutics
Incidence (epidemiology)
Obstetrics and Gynecology
Drugs
Neurodegenerative Diseases
Contraceptives
Middle Aged
3. Good health
Contraceptives
Oral
Combined

Contraception
Neurology
Physiological Parameters
Research Design
Female
Disease Susceptibility
medicine.drug
Research Article
Biotechnology
Adult
Risk
medicine.medical_specialty
Multiple Sclerosis
Adolescent
Contraceptive Therapy
Population
Immunology
Research and Analysis Methods
Autoimmune Diseases
Oral Contraceptive Therapy
03 medical and health sciences
Young Adult
Drug Therapy
Internal medicine
medicine
Humans
Female Contraception
Obesity
education
Retrospective Studies
Gynecology
Pharmacology
business.industry
lcsh:R
Body Weight
Case-control study
Biology and Life Sciences
Retrospective cohort study
Drospirenone
Estrogens
Demyelinating Disorders
Hormones
Case-Control Studies
Women's Health
lcsh:Q
Clinical Immunology
Medical Devices and Equipment
Clinical Medicine
Progestins
business
Body mass index
030217 neurology & neurosurgery
Zdroj: PLoS ONE
PLoS ONE, Vol 11, Iss 3, p e0149094 (2016)
ISSN: 1932-6203
Popis: BACKGROUND:The incidence of multiple sclerosis (MS) is rising in women. OBJECTIVE:To determine whether the use of combined oral contraceptives (COCs) are associated with MS risk and whether this varies by progestin content. METHODS:We conducted a nested case-control study of females ages 14-48 years with incident MS or clinically isolated syndrome (CIS) 2008-2011 from the membership of Kaiser Permanente Southern California. Controls were matched on age, race/ethnicity and membership characteristics. COC use up to ten years prior to symptom onset was obtained from the complete electronic health record. RESULTS:We identified 400 women with incident MS/CIS and 3904 matched controls. Forty- percent of cases and 32% of controls had used COCs prior to symptom onset. The use of COCs was associated with a slightly increased risk of MS/CIS (adjusted OR = 1.52, 95%CI = 1.21-1.91; p
Databáze: OpenAIRE